2019
DOI: 10.1111/jnc.14713
|View full text |Cite
|
Sign up to set email alerts
|

Antibodies against alpha‐synuclein: tools and therapies

Abstract: Synucleinopathies including Parkinson's disease, dementia with Lewy bodies and multiple system atrophy are characterized by the abnormal accumulation and propagation of α‐synuclein (α‐syn) pathology in the central and peripheral nervous system as Lewy bodies or glial cytoplasmic inclusions. Several antibodies against α‐syn have been developed since it was first detected as the major component of Lewy bodies and glial cytoplasmic inclusions. Over the years, researchers have generated specific antibodies that al… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

1
48
0

Year Published

2019
2019
2024
2024

Publication Types

Select...
5
2
2

Relationship

0
9

Authors

Journals

citations
Cited by 62 publications
(49 citation statements)
references
References 178 publications
(305 reference statements)
1
48
0
Order By: Relevance
“…Antibodies are also useful in clinical research, as diagnostic tools and, more recently, as biological therapies (Figure ). Given their specificity, there has been a great interest, and hope, in developing and applying immunotherapy for the treatment of neurodegenerative diseases, such as Alzheimer's disease, PD, and other synucleinopathies (Vaikath et al, ). Antibodies have several key features such as strong binding to the antigen, a long half life because of the constant part of the immunoglobulin, and the fact that they are occur naturally in the organism.…”
Section: Antibodies Against Asyn: Tools and Therapiesmentioning
confidence: 99%
See 1 more Smart Citation
“…Antibodies are also useful in clinical research, as diagnostic tools and, more recently, as biological therapies (Figure ). Given their specificity, there has been a great interest, and hope, in developing and applying immunotherapy for the treatment of neurodegenerative diseases, such as Alzheimer's disease, PD, and other synucleinopathies (Vaikath et al, ). Antibodies have several key features such as strong binding to the antigen, a long half life because of the constant part of the immunoglobulin, and the fact that they are occur naturally in the organism.…”
Section: Antibodies Against Asyn: Tools and Therapiesmentioning
confidence: 99%
“…Likewise, questions like whether these antibodies are able to cross the blood‐brain barrier and their ability to be internalized by the cells still need to be addressed. Determining the affinity and avidity of the antibodies, and further advances in developing smaller antibodies will also be important (Vaikath et al, ).…”
Section: Antibodies Against Asyn: Tools and Therapiesmentioning
confidence: 99%
“…To determine if intrastriatal injection of murine α-syn PFF reliably induced propagation of fibrillar α-syn in our mice, we first performed immunohistochemistry against pSER129-αsyn on sections of both brain hemispheres 13 days and 90 days after they had been injected with PFFs (13 dpi, 90 dpi). Immunostaining for pSER129-α-syn is the most commonly used approach to detect -syn inclusions in rodent or human brain tissues [56].…”
Section: Intrastriatal Injection Of Pffs Causes Bilateral -Syn Inclusmentioning
confidence: 99%
“…In contrast, antibody mediated immunodetection, is a conventional approach for specific detection of αSyn. Hereby, a large number of αSyn targeting antibodies, including conformation specific-ones and engineered antibody fragments are commonly utilized in a variety of applications 46,47 . In the recent years, camelid-originated single domain antibodies, also termed nanobodies, emerged as a promising alternative as they confer several advantages including recombinant production, enhanced tissue penetration, high stability, ideal for super-resolution microscopy and the ability to be expressed as intrabodies in mammalian cells [48][49][50] .…”
Section: Introduction α-Synuclein (αSyn) Aggregation Disorders Includmentioning
confidence: 99%